Company intelligence / Profile preview
Algen Biotechnologies
- Ownership
- Private
- Development stage
- Preclinical
Overview
Algen Biotechnologies has developed a proprietary CRISPR-based functional genomics platform combined with advanced AI to identify novel therapeutic targets by reverse engineering disease trajectories at single-cell resolution. Their lead programs are in preclinical development, focusing on first-in-class drugs that modulate disease-driving RNA messages. The company partners with major pharmaceutical companies to deploy its technology across multiple indications including cancer and inflammation.
- Therapeutic areas
- OncologyImmunologyOther
- Modalities
- Gene modulation (CRISPR-based)RNA-targeting therapeuticsAI-driven drug discovery
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Algen Biotechnologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Algen Biotechnologies.